Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2. The ...

Get a list of the most promising stocks in the semiconductors market & why investors believe in them. We will consider the impact of AI & where the industry is headed.

Main News Portal Global defence news, analysis and data insights across air, land, naval and military training. Shephard’s team of expert journalists cover new equipment and technology coverage, ...